Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.32 |
| ▸ | SGPL1 | O95470 | 4/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413107 | 1.00 | SLC5A2 (0.35) | SLC5A2SLC5A1CYP19A1CYP26A1S1PR1 | |
| SCHEMBL13108823 | 0.86 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3413103 | 0.84 | SLC5A2 (0.37) | SLC5A2SLC5A1CYP19A1CYP26A1S1PR1 | |
| SCHEMBL3414099 | 0.83 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL3414101 | 0.83 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL3411014 | 0.83 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL3411018 | 0.83 | SLC5A2 (0.39) | SLC5A2SLC5A1 | |
| SCHEMBL3411865 | 0.82 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3411874 | 0.82 | SLC5A2 (0.50) | SLC5A2SLC5A1 | |
| SCHEMBL3413156 | 0.81 | SLC5A2 (0.44) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | PATEL MONA | 2009-04-16 | — | — | US | claimed |
| US-7084124-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-01 | — | — | US | claimed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | claimed |
| US-7816331-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | PATEL MONA | 2010-03-11 | — | — | US | disclosed |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | PATEL MONA | 2009-04-16 | — | — | US | disclosed |
| US-7511021-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060217323-A1 | Substituted indazole-O-glucosides | Tanabe Pharma Corporation (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7084124-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-01 | — | — | US | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | SLC5A2 10/4885SLC5A1 9/4885CYP19A1 232/4885 |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | GYS2, GPR119, UGGT1 | SLC5A2 10/4885SLC5A1 9/4885CYP19A1 232/4885 |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | GYS2, GPR119, PYGL | SLC5A2 10/4885SLC5A1 11/4885CYP19A1 228/4885 |
| US-20060217323-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | SLC5A2 10/4885SLC5A1 9/4885CYP19A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.